Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Expectations By $0.70 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) announced its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70, Yahoo Finance reports. The firm had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million.

Day One Biopharmaceuticals Price Performance

DAWN stock traded down $0.51 during midday trading on Wednesday, reaching $14.68. 1,531,904 shares of the company were exchanged, compared to its average volume of 908,107. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $18.07. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.65 and a beta of -1.51. The business has a 50-day moving average price of $14.01 and a two-hundred day moving average price of $14.84.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Friday, July 26th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Piper Sandler restated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Insider Activity

In related news, CEO Jeremy Bender sold 9,154 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $163,398.90. Following the transaction, the chief executive officer now owns 642,602 shares in the company, valued at approximately $11,470,445.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Samuel C. Blackman sold 2,267 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total transaction of $36,453.36. Following the sale, the insider now owns 1,171,081 shares of the company’s stock, valued at $18,830,982.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $163,398.90. Following the completion of the transaction, the chief executive officer now directly owns 642,602 shares of the company’s stock, valued at $11,470,445.70. The disclosure for this sale can be found here. Insiders have sold 73,300 shares of company stock valued at $1,181,765 over the last ninety days. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.